CN103349664A - 含甾族的c-17苯并吡咯的组合物 - Google Patents

含甾族的c-17苯并吡咯的组合物 Download PDF

Info

Publication number: CN103349664A
Authority: CN; China
Prior art keywords: compound; treatment; compounds; diene; prostate cancer
Prior art date: 2005-03-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN2013101036754A

Other languages

English (en)

Chinese (zh)

Inventor

A·布罗迪

V·恩雅

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Maryland College Park

Original Assignee

University of Maryland College Park

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-02

Filing date

2006-03-02

Publication date

2013-10-16

2006-03-02 Application filed by University of Maryland College Park filed Critical University of Maryland College Park

2013-10-16 Publication of CN103349664A publication Critical patent/CN103349664A/zh

Status Pending legal-status Critical Current

Links

SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title abstract description 13
230000003637 steroidlike Effects 0.000 title abstract description 8
206010060862 Prostate cancer Diseases 0.000 claims abstract description 61
208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 60
238000011282 treatment Methods 0.000 claims abstract description 56
239000000203 mixture Substances 0.000 claims abstract description 18
150000001875 compounds Chemical class 0.000 claims description 90
238000007920 subcutaneous administration Methods 0.000 claims description 15
206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 7
208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 6
208000017497 prostate disease Diseases 0.000 claims description 5
230000000699 topical effect Effects 0.000 claims description 3
239000000443 aerosol Substances 0.000 claims description 2
238000007918 intramuscular administration Methods 0.000 claims description 2
238000007912 intraperitoneal administration Methods 0.000 claims description 2
238000007913 intrathecal administration Methods 0.000 claims description 2
238000001990 intravenous administration Methods 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
239000007921 spray Substances 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims 1
238000001361 intraarterial administration Methods 0.000 claims 1
201000004240 prostatic hypertrophy Diseases 0.000 claims 1
102000001307 androgen receptors Human genes 0.000 abstract description 40
108010080146 androgen receptors Proteins 0.000 abstract description 40
230000003389 potentiating effect Effects 0.000 abstract description 39
239000003112 inhibitor Substances 0.000 abstract description 19
102000004190 Enzymes Human genes 0.000 abstract description 17
108090000790 Enzymes Proteins 0.000 abstract description 17
238000006467 substitution reaction Methods 0.000 abstract description 8
239000005557 antagonist Substances 0.000 abstract description 6
238000003379 elimination reaction Methods 0.000 abstract description 6
DHZJEYGWSNDRGN-USOAJAOKSA-N (3s,8r,9s,10r,13s,14s)-17-iodo-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(=CC4)I)[C@@H]4[C@@H]3CC=C21 DHZJEYGWSNDRGN-USOAJAOKSA-N 0.000 abstract description 5
KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical class C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 abstract description 5
150000004891 diazines Chemical class 0.000 abstract description 4
230000000269 nucleophilic effect Effects 0.000 abstract description 3
101100329172 Homo sapiens CYP17A1 gene Proteins 0.000 abstract description 2
DBHSVKZZSWTSTN-UHFFFAOYSA-N tributyl(pyridazin-3-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CN=N1 DBHSVKZZSWTSTN-UHFFFAOYSA-N 0.000 abstract description 2
238000006880 cross-coupling reaction Methods 0.000 abstract 1
238000010189 synthetic method Methods 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 description 59
241000699670 Mus sp. Species 0.000 description 37
230000000694 effects Effects 0.000 description 37
239000003098 androgen Substances 0.000 description 29
238000000034 method Methods 0.000 description 26
102000001854 Steroid 17-alpha-Hydroxylase Human genes 0.000 description 25
108010015330 Steroid 17-alpha-Hydroxylase Proteins 0.000 description 25
229940124766 Cyp17 inhibitor Drugs 0.000 description 23
230000015572 biosynthetic process Effects 0.000 description 22
238000003786 synthesis reaction Methods 0.000 description 20
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 19
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 19
230000002401 inhibitory effect Effects 0.000 description 19
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
230000005764 inhibitory process Effects 0.000 description 18
239000002207 metabolite Substances 0.000 description 18
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
229960003473 androstanolone Drugs 0.000 description 17
230000002280 anti-androgenic effect Effects 0.000 description 17
239000000051 antiandrogen Substances 0.000 description 17
238000001727 in vivo Methods 0.000 description 17
229940125898 compound 5 Drugs 0.000 description 16
230000012010 growth Effects 0.000 description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
238000002844 melting Methods 0.000 description 14
230000008018 melting Effects 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
108060001084 Luciferase Proteins 0.000 description 13
239000005089 Luciferase Substances 0.000 description 13
241001465754 Metazoa Species 0.000 description 13
238000003556 assay Methods 0.000 description 13
201000011510 cancer Diseases 0.000 description 13
238000004896 high resolution mass spectrometry Methods 0.000 description 13
238000011579 SCID mouse model Methods 0.000 description 12
238000002474 experimental method Methods 0.000 description 12
238000004128 high performance liquid chromatography Methods 0.000 description 12
230000004614 tumor growth Effects 0.000 description 12
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
230000001093 anti-cancer Effects 0.000 description 11
238000000338 in vitro Methods 0.000 description 11
150000003431 steroids Chemical class 0.000 description 11
210000001519 tissue Anatomy 0.000 description 11
LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 10
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
239000012964 benzotriazole Chemical group 0.000 description 10
229940097647 casodex Drugs 0.000 description 10
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
235000019439 ethyl acetate Nutrition 0.000 description 9
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 8
PRBTWKCJXZGRAL-BLQWBTBKSA-N (3s,8r,9s,10r,13s,14s)-17-imidazol-1-yl-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1N1C=CN=C1 PRBTWKCJXZGRAL-BLQWBTBKSA-N 0.000 description 8
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical group C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 8
230000001419 dependent effect Effects 0.000 description 8
229960002074 flutamide Drugs 0.000 description 8
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 8
229960004125 ketoconazole Drugs 0.000 description 8
239000002609 medium Substances 0.000 description 8
-1 pyrimidopyrrole (azabenzopyrrole) Chemical compound 0.000 description 8
230000009467 reduction Effects 0.000 description 8
238000010992 reflux Methods 0.000 description 8
239000000243 solution Substances 0.000 description 8
210000001550 testis Anatomy 0.000 description 8
GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical group N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 description 7
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 7
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 7
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 7
238000011474 orchiectomy Methods 0.000 description 7
239000012071 phase Substances 0.000 description 7
230000003442 weekly effect Effects 0.000 description 7
JPMBLPVHJHQFHR-HKGZJRCASA-N (8r,9s,10r,13s,14s)-17-(benzimidazol-1-yl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=NC2=CC=CC=C2N1C1=CC[C@H]2[C@H](CCC=3[C@@]4(CCC(=O)C=3)C)[C@@H]4CC[C@@]21C JPMBLPVHJHQFHR-HKGZJRCASA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
229960000853 abiraterone Drugs 0.000 description 6
GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 6
230000004663 cell proliferation Effects 0.000 description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
230000036515 potency Effects 0.000 description 6
210000002307 prostate Anatomy 0.000 description 6
239000000758 substrate Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 5
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
238000001816 cooling Methods 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
230000014759 maintenance of location Effects 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
230000036470 plasma concentration Effects 0.000 description 5
NCMZQTLCXHGLOK-ZKHIMWLXSA-N prasterone acetate Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 NCMZQTLCXHGLOK-ZKHIMWLXSA-N 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
239000000126 substance Substances 0.000 description 5
229960003604 testosterone Drugs 0.000 description 5
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 4
PAFKTGFSEFKSQG-PAASFTFBSA-N Galeterone Chemical compound C1=NC2=CC=CC=C2N1C1=CC[C@H]2[C@H](CC=C3[C@@]4(CC[C@H](O)C3)C)[C@@H]4CC[C@@]21C PAFKTGFSEFKSQG-PAASFTFBSA-N 0.000 description 4
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 description 4
210000004100 adrenal gland Anatomy 0.000 description 4
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 4
230000010261 cell growth Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
239000012043 crude product Substances 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
125000005331 diazinyl group Chemical group N1=NC(=CC=C1)* 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
239000000284 extract Substances 0.000 description 4
230000014509 gene expression Effects 0.000 description 4
150000003278 haem Chemical class 0.000 description 4
239000005457 ice water Substances 0.000 description 4
229910052742 iron Inorganic materials 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
229910052763 palladium Inorganic materials 0.000 description 4
239000003208 petroleum Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
108010042121 probasin Proteins 0.000 description 4
239000000047 product Substances 0.000 description 4
208000023958 prostate neoplasm Diseases 0.000 description 4
239000007787 solid Substances 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 3
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical class C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 3
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 3
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 3
102000018832 Cytochromes Human genes 0.000 description 3
108010052832 Cytochromes Proteins 0.000 description 3
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 3
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
239000012980 RPMI-1640 medium Substances 0.000 description 3
229960004103 abiraterone acetate Drugs 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
229940030486 androgens Drugs 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
150000001556 benzimidazoles Chemical class 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
OVBXTKIWZAHFAC-UHFFFAOYSA-N butane;pyrazine;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CN=CC=N1 OVBXTKIWZAHFAC-UHFFFAOYSA-N 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
230000008859 change Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
229940125797 compound 12 Drugs 0.000 description 3
229940125758 compound 15 Drugs 0.000 description 3
229940126142 compound 16 Drugs 0.000 description 3
229940126214 compound 3 Drugs 0.000 description 3
230000034994 death Effects 0.000 description 3
FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 3
230000008030 elimination Effects 0.000 description 3
DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 3
229960004039 finasteride Drugs 0.000 description 3
230000036541 health Effects 0.000 description 3
125000001072 heteroaryl group Chemical group 0.000 description 3
150000007857 hydrazones Chemical class 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
239000011630 iodine Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
235000015320 potassium carbonate Nutrition 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
230000008569 process Effects 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
230000000306 recurrent effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 3
QRDQHTJNKPXXRQ-UHFFFAOYSA-N tributyl(pyrimidin-5-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CN=CN=C1 QRDQHTJNKPXXRQ-UHFFFAOYSA-N 0.000 description 3
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
229920002554 vinyl polymer Polymers 0.000 description 3
239000008096 xylene Substances 0.000 description 3
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
MDHIWBNJNHUBJL-VMXHOPILSA-N (8s,9s,10r,13r,14s)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CC=C21 MDHIWBNJNHUBJL-VMXHOPILSA-N 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 2
150000000183 1,3-benzoxazoles Chemical class 0.000 description 2
SYOANZBNGDEJFH-UHFFFAOYSA-N 2,5-dihydro-1h-triazole Chemical compound C1NNN=C1 SYOANZBNGDEJFH-UHFFFAOYSA-N 0.000 description 2
FUSNOPLQVRUIIM-UHFFFAOYSA-N 4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-n-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide Chemical compound O=C1NC(C)(C)CN1C(N=C1N)=NC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 FUSNOPLQVRUIIM-UHFFFAOYSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
102100029648 Beta-arrestin-2 Human genes 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 2
238000010268 HPLC based assay Methods 0.000 description 2
101000728661 Homo sapiens Beta-arrestin-2 Proteins 0.000 description 2
108010044467 Isoenzymes Proteins 0.000 description 2
108010000817 Leuprolide Proteins 0.000 description 2
101150053185 P450 gene Proteins 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 2
239000004809 Teflon Substances 0.000 description 2
229920006362 Teflon® Polymers 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000000556 agonist Substances 0.000 description 2
125000006294 amino alkylene group Chemical group 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
239000012267 brine Substances 0.000 description 2
238000011088 calibration curve Methods 0.000 description 2
150000001721 carbon Chemical group 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000003610 charcoal Substances 0.000 description 2
229940125773 compound 10 Drugs 0.000 description 2
229940125782 compound 2 Drugs 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
230000001085 cytostatic effect Effects 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
238000010586 diagram Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000036267 drug metabolism Effects 0.000 description 2
QGXBDMJGAMFCBF-LUJOEAJASA-N epiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-LUJOEAJASA-N 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
229960003132 halothane Drugs 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
239000012493 hydrazine sulfate Substances 0.000 description 2
229910000377 hydrazine sulfate Inorganic materials 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
238000005462 in vivo assay Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
229960004338 leuprorelin Drugs 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000002697 lyase inhibitor Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
239000002547 new drug Substances 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
238000007747 plating Methods 0.000 description 2
229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
229960002847 prasterone Drugs 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
239000001294 propane Substances 0.000 description 2
201000001514 prostate carcinoma Diseases 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
239000010948 rhodium Substances 0.000 description 2
JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000004611 spectroscopical analysis Methods 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000001890 transfection Methods 0.000 description 2
238000012546 transfer Methods 0.000 description 2
AEMFNILZOJDQLW-WFZCBACDSA-N (10r,13s)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1CC[C@]2(C)C3CC[C@](C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-WFZCBACDSA-N 0.000 description 1
AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
QVHPTAJAHUONLV-FZFXZXLVSA-N (8s,9s,10r,13r,14s)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1C(O)CC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CC=C21 QVHPTAJAHUONLV-FZFXZXLVSA-N 0.000 description 1
LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-Bis(diphenylphosphino)propane Substances C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 1
SPEDTVSELPTCNP-HKGZJRCASA-N 1-[(8r,9s,10r,13s,14s)-10,13-dimethyl-2,7,8,9,11,12,14,15-octahydro-1h-cyclopenta[a]phenanthren-17-yl]benzimidazole Chemical compound C1=NC2=CC=CC=C2N1C1=CC[C@H]2[C@H](CC=C3[C@@]4(CCC=C3)C)[C@@H]4CC[C@@]21C SPEDTVSELPTCNP-HKGZJRCASA-N 0.000 description 1
DCQGLGJSBKJCEI-HKGZJRCASA-N 1-[(8r,9s,10r,13s,14s)-10,13-dimethyl-6,7,8,9,11,12,14,15-octahydro-1h-cyclopenta[a]phenanthren-17-yl]benzimidazole Chemical compound C1=NC2=CC=CC=C2N1C1=CC[C@H]2[C@H](CCC=3[C@@]4(CC=CC=3)C)[C@@H]4CC[C@@]21C DCQGLGJSBKJCEI-HKGZJRCASA-N 0.000 description 1
RXNKMNIUGFALMH-COKZPPKWSA-N 1-[(8r,9s,10r,13s,14s)-3,3-difluoro-10,13-dimethyl-1,2,4,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-17-yl]benzimidazole Chemical compound C1=NC2=CC=CC=C2N1C1=CC[C@H]2[C@H](CC=C3[C@@]4(CCC(F)(F)C3)C)[C@@H]4CC[C@@]21C RXNKMNIUGFALMH-COKZPPKWSA-N 0.000 description 1
YOKGGZYKOPTMHZ-COKZPPKWSA-N 1-[(8r,9s,10r,13s,14s)-3,3-difluoro-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-17-yl]benzimidazole Chemical compound C1=NC2=CC=CC=C2N1C1=CC[C@H]2[C@H](CCC=3[C@@]4(CCC(F)(F)C=3)C)[C@@H]4CC[C@@]21C YOKGGZYKOPTMHZ-COKZPPKWSA-N 0.000 description 1
UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
IMFYNUCSWSEWIX-UHFFFAOYSA-N 1h-benzimidazole;2h-benzotriazole Chemical compound C1=CC=C2NC=NC2=C1.C1=CC=C2NN=NC2=C1 IMFYNUCSWSEWIX-UHFFFAOYSA-N 0.000 description 1
SEBPXHSZHLFWRL-UHFFFAOYSA-N 3,4-dihydro-2,2,5,7,8-pentamethyl-2h-1-benzopyran-6-ol Chemical compound O1C(C)(C)CCC2=C1C(C)=C(C)C(O)=C2C SEBPXHSZHLFWRL-UHFFFAOYSA-N 0.000 description 1
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
108010029908 3-oxo-5-alpha-steroid 4-dehydrogenase Proteins 0.000 description 1
102000001779 3-oxo-5-alpha-steroid 4-dehydrogenase Human genes 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
LDIOUQIXNSSOGU-UHFFFAOYSA-N 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5h-cyclopenta[d]pyrazolo[1,5-a]pyrimidine Chemical compound CC1=NN2C(NC(CC)CC)=C3CCCC3=NC2=C1C1=CC=C(OC)C=C1Cl LDIOUQIXNSSOGU-UHFFFAOYSA-N 0.000 description 1
229940127512 Androgen Synthesis Inhibitors Drugs 0.000 description 1
229940123407 Androgen receptor antagonist Drugs 0.000 description 1
238000010152 Bonferroni least significant difference Methods 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010010099 Combined immunodeficiency Diseases 0.000 description 1
229940126657 Compound 17 Drugs 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
102000011088 Cytochrome P450 Family 17 Human genes 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
239000001116 FEMA 4028 Substances 0.000 description 1
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
206010019851 Hepatotoxicity Diseases 0.000 description 1
101000934888 Homo sapiens Succinate dehydrogenase cytochrome b560 subunit, mitochondrial Proteins 0.000 description 1
206010071119 Hormone-dependent prostate cancer Diseases 0.000 description 1
206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
102000004317 Lyases Human genes 0.000 description 1
108090000856 Lyases Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
WVBYPUDVOAKTOE-UHFFFAOYSA-N N1=CC=NC=C1.N1=CN=CC=C1.N1N=NC2=C1C=NC=N2 Chemical compound N1=CC=NC=C1.N1=CN=CC=C1.N1N=NC2=C1C=NC=N2 WVBYPUDVOAKTOE-UHFFFAOYSA-N 0.000 description 1
GIHJFWVNPZEVMU-UHFFFAOYSA-N N1C=NC=C2C1=CC=N2.N2C=NC=C1C2=CC=N1 Chemical compound N1C=NC=C2C1=CC=N2.N2C=NC=C1C2=CC=N1 GIHJFWVNPZEVMU-UHFFFAOYSA-N 0.000 description 1
101710198130 NADPH-cytochrome P450 reductase Proteins 0.000 description 1
239000007832 Na2SO4 Substances 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
108091007187 Reductases Proteins 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
102100025393 Succinate dehydrogenase cytochrome b560 subunit, mitochondrial Human genes 0.000 description 1
LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
UVIQSJCZCSLXRZ-CKFSHRNPSA-N [(3s,8r,9r,10r,13s,14s)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-CKFSHRNPSA-N 0.000 description 1
CGNVCEBCRNNHAV-UHFFFAOYSA-N [N].C1=CC=C2OC=NC2=C1 Chemical compound [N].C1=CC=C2OC=NC2=C1 CGNVCEBCRNNHAV-UHFFFAOYSA-N 0.000 description 1
HUTKMNBINBEHQC-UHFFFAOYSA-N [Rh+].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 Chemical compound [Rh+].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 HUTKMNBINBEHQC-UHFFFAOYSA-N 0.000 description 1
238000002679 ablation Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
239000012491 analyte Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000009167 androgen deprivation therapy Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
239000013059 antihormonal agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
238000013459 approach Methods 0.000 description 1
XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
150000001562 benzopyrans Chemical class 0.000 description 1
150000001565 benzotriazoles Chemical class 0.000 description 1
FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
235000011175 beta-cyclodextrine Nutrition 0.000 description 1
229960004853 betadex Drugs 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical group S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000003570 cell viability assay Methods 0.000 description 1
238000011208 chromatographic data Methods 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002131 composite material Substances 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
229940126543 compound 14 Drugs 0.000 description 1
229940125810 compound 20 Drugs 0.000 description 1
229940126086 compound 21 Drugs 0.000 description 1
229940126208 compound 22 Drugs 0.000 description 1
229940125833 compound 23 Drugs 0.000 description 1
229940125961 compound 24 Drugs 0.000 description 1
229940125846 compound 25 Drugs 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000006198 deformylation Effects 0.000 description 1
238000006344 deformylation reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000009261 endocrine therapy Methods 0.000 description 1
229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 1
239000002024 ethyl acetate extract Substances 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
125000000262 haloalkenyl group Chemical group 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
230000007686 hepatotoxicity Effects 0.000 description 1
231100000304 hepatotoxicity Toxicity 0.000 description 1
238000001794 hormone therapy Methods 0.000 description 1
208000018821 hormone-resistant prostate carcinoma Diseases 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
YPQLFJODEKMJEF-UHFFFAOYSA-N hydroxyflutamide Chemical compound CC(C)(O)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 YPQLFJODEKMJEF-UHFFFAOYSA-N 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000005917 in vivo anti-tumor Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
150000002473 indoazoles Chemical class 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000006317 isomerization reaction Methods 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
150000002611 lead compounds Chemical class 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
238000003670 luciferase enzyme activity assay Methods 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
108010082117 matrigel Proteins 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
229960002455 methoxyflurane Drugs 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000008450 motivation Effects 0.000 description 1
QOZSSQJVNGFTLA-HKGZJRCASA-N n-[(8r,9s,10r,13s,14s)-17-(benzimidazol-1-yl)-10,13-dimethyl-1,2,4,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-ylidene]hydroxylamine Chemical compound C1=NC2=CC=CC=C2N1C1=CC[C@H]2[C@H](CC=C3[C@@]4(CCC(C3)=NO)C)[C@@H]4CC[C@@]21C QOZSSQJVNGFTLA-HKGZJRCASA-N 0.000 description 1
ACBMPZRTBKJNKP-HKGZJRCASA-N n-[(8r,9s,10r,13s,14s)-17-(benzimidazol-1-yl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-ylidene]hydroxylamine Chemical compound C1=NC2=CC=CC=C2N1C1=CC[C@H]2[C@H](CCC=3[C@@]4(CCC(C=3)=NO)C)[C@@H]4CC[C@@]21C ACBMPZRTBKJNKP-HKGZJRCASA-N 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
239000012038 nucleophile Substances 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
239000013641 positive control Substances 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
102000003998 progesterone receptors Human genes 0.000 description 1
108090000468 progesterone receptors Proteins 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
201000005825 prostate adenocarcinoma Diseases 0.000 description 1
210000005267 prostate cell Anatomy 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
229960005206 pyrazinamide Drugs 0.000 description 1
238000011002 quantification Methods 0.000 description 1
239000002994 raw material Substances 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000007670 refining Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000011808 rodent model Methods 0.000 description 1
238000005464 sample preparation method Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010183 spectrum analysis Methods 0.000 description 1
238000012421 spiking Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
108010085954 steroid-5alpha-reductase type 2 Proteins 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
230000002381 testicular Effects 0.000 description 1
229940098465 tincture Drugs 0.000 description 1
238000006257 total synthesis reaction Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
229960002117 triamcinolone acetonide Drugs 0.000 description 1
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
CCXFZGWHOYXGHW-UHFFFAOYSA-N trimethyl(pyrimidin-5-yl)stannane Chemical compound C[Sn](C)(C)C1=CN=CN=C1 CCXFZGWHOYXGHW-UHFFFAOYSA-N 0.000 description 1
XZZNDPSIHUTMOC-UHFFFAOYSA-N triphenyl phosphate Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)(=O)OC1=CC=CC=C1 XZZNDPSIHUTMOC-UHFFFAOYSA-N 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
230000002100 tumorsuppressive effect Effects 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
231100000747 viability assay Toxicity 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CN2013101036754A 2005-03-02 2006-03-02 含甾族的c-17苯并吡咯的组合物 Pending CN103349664A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US65739005P	2005-03-02	2005-03-02
US60/657,390		2005-03-02

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CNA2006800064632A Division CN101155823A (zh)	2005-03-02	2006-03-02	新的c-17-杂芳基甾族的cyp17抑制剂/抗雄激素物质：其合成，体外生物学活性，药代动力学和抗肿瘤活性

Publications (1)

Publication Number	Publication Date
CN103349664A true CN103349664A (zh)	2013-10-16

Family

ID=36941503

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CN2013101036754A Pending CN103349664A (zh)	2005-03-02	2006-03-02	含甾族的c-17苯并吡咯的组合物
CNA2006800064632A Pending CN101155823A (zh)	2005-03-02	2006-03-02	新的c-17-杂芳基甾族的cyp17抑制剂/抗雄激素物质：其合成，体外生物学活性，药代动力学和抗肿瘤活性

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CNA2006800064632A Pending CN101155823A (zh)	2005-03-02	2006-03-02	新的c-17-杂芳基甾族的cyp17抑制剂/抗雄激素物质：其合成，体外生物学活性，药代动力学和抗肿瘤活性

Country Status (21)

Country	Link
US (1)	US7875599B2 (2)
EP (2)	EP2206719B1 (2)
JP (2)	JP5130453B2 (2)
KR (1)	KR101380959B1 (2)
CN (2)	CN103349664A (2)
AT (1)	ATE482969T1 (2)
AU (1)	AU2006218711B2 (2)
BR (1)	BRPI0607523A2 (2)
CA (1)	CA2599953C (2)
DE (1)	DE602006017175D1 (2)
DK (2)	DK1853619T3 (2)
EA (1)	EA019560B1 (2)
ES (2)	ES2528055T3 (2)
IL (3)	IL185608A (2)
MX (1)	MX2007010593A (2)
NZ (1)	NZ561571A (2)
PL (2)	PL1853619T3 (2)
PT (2)	PT2206719E (2)
SI (2)	SI1853619T1 (2)
WO (1)	WO2006093993A1 (2)
ZA (1)	ZA200708106B (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN105732759A (zh) *	2015-01-29	2016-07-06	苏州晶云药物科技有限公司	(3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8569275B2 (en)	2002-08-28	2013-10-29	Harbor Therapeutics, Inc.	Steroids having 7-oxgen and 17-heteroaryl substitution
US7875599B2 (en) *	2005-03-02	2011-01-25	University Of Maryland	C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity
EP2167090A4 (en)	2007-06-06	2010-08-25	Univ Maryland	HDAC INHIBITORS AND HORMONE TREATMENT MEDICAMENTS
GB2470873A (en) *	2008-03-12	2010-12-08	Univ Maryland	Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitors in prostrate cancer
US20100048524A1 (en) *	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
GB2470700B (en) *	2008-03-25	2012-08-08	Univ Maryland	C-17 heteroaryl steroidal CYP17 inhibitors
US8785423B2 (en) *	2008-04-14	2014-07-22	University Of Maryland, Baltimore	Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
EP2334686B1 (en)	2008-08-28	2019-02-27	President and Fellows of Harvard College	Cortistatin analogues and syntheses therof
EP2362872A4 (en) *	2008-10-28	2012-05-30	Biomarin Pharm Inc	DECAHYDRO-1H-INDENOCHINOLINONE AND DECAHYDRO-3H-CYCLOPENTAPHENANTHRIDINONE CYP17 HEMMER
GB2479337A (en) *	2009-02-05	2011-10-05	Tokai Pharmaceuticals Inc	Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
WO2010091306A1 (en)	2009-02-05	2010-08-12	Tokai Pharmaceuticals	Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2010091303A1 (en) *	2009-02-05	2010-08-12	Tokai Pharmaceuticals	Novel steroidal cyp17 inhibitors/antiandrogens
UY32730A (es)	2009-06-26	2011-01-31	Novartis Ag	Inhibidores de cyp17
WO2011017534A2 (en)	2009-08-07	2011-02-10	Tokai Pharmaceuticals, Inc.	Treatment of prostate cancer
EP2499151A4 (en) *	2009-11-13	2013-03-20	Tokai Pharmaceuticals Inc	MAMMALIAN STEROID METABOLITES
EP2506855A4 (en) *	2009-11-30	2014-07-30	Harbor Biosciences Inc	ANTICARCINOMA COMPOUNDS AND SCREENING METHODS
US8946260B2 (en)	2010-09-16	2015-02-03	Novartis Ag	17α-hydroxylase/C17,20-lyase inhibitors
AU2011343637A1 (en) *	2010-12-16	2013-05-30	Biomarin Pharmaceutical Inc.	C- 17 -heteroaryl steroidal compounds as inhibitors of CYP11B, CYP17, and/or CYP21
AU2012249421B9 (en)	2011-04-28	2015-10-22	Novartis Ag	17alpha-hydroxylase/C17,20-lyase inhibitors
BR112014001440A2 (pt) *	2011-07-18	2017-02-21	Tokai Pharmaceuticals Inc	novas composições e métodos para o tratamento de câncer de próstata
AU2012358219A1 (en) *	2011-12-22	2014-07-10	Tokai Pharmaceuticals, Inc.	Methods and compositions for combination therapy using P13K/mTOR inhibitors
KR20150127720A (ko)	2013-03-14	2015-11-17	유니버시티 오브 매릴랜드, 발티모어	안드로겐 수용체 하향 조절제 및 그의 용도
US9694005B2 (en)	2013-04-04	2017-07-04	University Of Maryland, Baltimore	Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
CA2920317A1 (en)	2013-08-12	2015-02-19	Tokai Pharmaceuticals, Inc.	Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
SG11201605178WA (en)	2013-12-24	2016-07-28	Harvard College	Cortistatin analogues and syntheses and uses thereof
CN103694299A (zh) *	2014-01-13	2014-04-02	中国药科大学	甾体类雄激素受体抑制剂、其制备方法及其医药用途
WO2016182932A1 (en)	2015-05-08	2016-11-17	President And Fellows Of Harvard College	Cortistatin analogues, syntheses, and uses thereof
WO2017004411A1 (en)	2015-07-01	2017-01-05	President And Fellows Of Harvard College	Cortistatin analogues and syntheses and uses thereof
US10682362B2 (en)	2015-10-14	2020-06-16	Wayne State University	Treatments and diagnostics for cancers
IT201600083406A1 (it) *	2016-08-08	2018-02-08	Ind Chimica Srl	PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
IT201600121375A1 (it) *	2016-11-30	2018-05-30	Ind Chimica Srl	PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
US11390645B2 (en)	2016-08-08	2022-07-19	Industriale Chimica S.R.L.	Process for the preparation of 3β-hydroxy-17-(1H-benzimidazol-1-YL) androsta-5,16-diene
CA3087286C (en)	2018-02-13	2023-06-27	Dana-Farber Cancer Institute, Inc.	Cyclin-dependent kinase degraders and methods of use
US20200369715A1 (en) *	2018-02-13	2020-11-26	Dana-Farber Cancer Institute, Inc.	Cyclin-dependent kinase inhibitors and methods of use
US12410194B2 (en)	2019-11-26	2025-09-09	Dana-Farber Cancer Institute, Inc.	Potent and selective azaindole inhibitors of CDK8 and CDK19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA27440A (en)		1887-08-16	James T. Walsh	Art of making sheet metal cans, for packing meats, fruits, vegetables, etc.
CH621803A5 (2) *	1974-08-08	1981-02-27	Siphar Sa
US5604213A (en) *	1992-03-31	1997-02-18	British Technology Group Limited	17-substituted steroids useful in cancer treatment
US5994335A (en) *	1997-10-17	1999-11-30	The University Of Maryland, Baltimore	17-azolyl steroids useful as androgen synthesis inhibitors
JP4855253B2 (ja)	2003-07-29	2012-01-18	ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ	幹細胞動員に有用な医薬の組み合わせ
US7875599B2 (en) *	2005-03-02	2011-01-25	University Of Maryland	C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity

2006
- 2006-03-02 US US11/817,550 patent/US7875599B2/en active Active
- 2006-03-02 BR BRPI0607523-1A patent/BRPI0607523A2/pt not_active IP Right Cessation
- 2006-03-02 PT PT101507630T patent/PT2206719E/pt unknown
- 2006-03-02 JP JP2007558143A patent/JP5130453B2/ja not_active Expired - Lifetime
- 2006-03-02 PL PL06736460T patent/PL1853619T3/pl unknown
- 2006-03-02 DK DK06736460.4T patent/DK1853619T3/da active
- 2006-03-02 CA CA2599953A patent/CA2599953C/en not_active Expired - Lifetime
- 2006-03-02 EP EP10150763.0A patent/EP2206719B1/en not_active Expired - Lifetime
- 2006-03-02 WO PCT/US2006/007143 patent/WO2006093993A1/en not_active Ceased
- 2006-03-02 ES ES10150763.0T patent/ES2528055T3/es not_active Expired - Lifetime
- 2006-03-02 MX MX2007010593A patent/MX2007010593A/es active IP Right Grant
- 2006-03-02 AT AT06736460T patent/ATE482969T1/de active
- 2006-03-02 PT PT06736460T patent/PT1853619E/pt unknown
- 2006-03-02 EA EA200701872A patent/EA019560B1/ru not_active IP Right Cessation
- 2006-03-02 EP EP06736460A patent/EP1853619B1/en not_active Expired - Lifetime
- 2006-03-02 AU AU2006218711A patent/AU2006218711B2/en not_active Expired
- 2006-03-02 DE DE602006017175T patent/DE602006017175D1/de not_active Expired - Lifetime
- 2006-03-02 ES ES06736460T patent/ES2353413T3/es not_active Expired - Lifetime
- 2006-03-02 DK DK10150763.0T patent/DK2206719T3/en active
- 2006-03-02 SI SI200630861T patent/SI1853619T1/sl unknown
- 2006-03-02 SI SI200631883T patent/SI2206719T1/sl unknown
- 2006-03-02 CN CN2013101036754A patent/CN103349664A/zh active Pending
- 2006-03-02 KR KR1020077022440A patent/KR101380959B1/ko not_active Expired - Fee Related
- 2006-03-02 PL PL10150763T patent/PL2206719T3/pl unknown
- 2006-03-02 NZ NZ561571A patent/NZ561571A/en not_active IP Right Cessation
- 2006-03-02 CN CNA2006800064632A patent/CN101155823A/zh active Pending
2007
- 2007-08-30 IL IL185608A patent/IL185608A/en not_active IP Right Cessation
- 2007-09-20 ZA ZA200708106A patent/ZA200708106B/xx unknown
2011
- 2011-01-06 IL IL210480A patent/IL210480A/en not_active IP Right Cessation
- 2011-01-06 IL IL210478A patent/IL210478A0/en unknown
2012
- 2012-09-06 JP JP2012196525A patent/JP5613206B2/ja not_active Expired - Lifetime

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OMOSHILE O. CLEMENT ET AL: "Three Dimensional Pharmacophore Modeling of Human CYP17 Inhibitors.Potential Agents for Prostate Cancer Therapy", 《J. MED. CHEM.》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN105732759A (zh) *	2015-01-29	2016-07-06	苏州晶云药物科技有限公司	(3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法

Also Published As

Publication number	Publication date
EP2206719B1 (en)	2014-10-22
ES2528055T3 (es)	2015-02-03
DK1853619T3 (da)	2011-01-10
KR20070120119A (ko)	2007-12-21
SI2206719T1 (sl)	2015-03-31
AU2006218711A2 (en)	2006-09-08
IL210478A0 (en)	2011-03-31
JP5130453B2 (ja)	2013-01-30
MX2007010593A (es)	2008-02-20
PT1853619E (pt)	2011-01-03
CA2599953A1 (en)	2006-09-08
WO2006093993A1 (en)	2006-09-08
EP1853619A4 (en)	2009-08-26
JP2012255026A (ja)	2012-12-27
DE602006017175D1 (de)	2010-11-11
IL210480A0 (en)	2011-03-31
EP1853619A1 (en)	2007-11-14
JP5613206B2 (ja)	2014-10-22
PT2206719E (pt)	2015-02-05
NZ561571A (en)	2009-09-25
EA200701872A1 (ru)	2008-06-30
ZA200708106B (en)	2008-12-31
AU2006218711B2 (en)	2010-11-11
AU2006218711A1 (en)	2006-09-08
BRPI0607523A2 (pt)	2009-09-08
PL1853619T3 (pl)	2011-03-31
IL210480A (en)	2015-06-30
US20080280864A1 (en)	2008-11-13
PL2206719T3 (pl)	2015-03-31
KR101380959B1 (ko)	2014-04-04
CA2599953C (en)	2013-08-13
DK2206719T3 (en)	2015-01-26
SI1853619T1 (sl)	2011-01-31
JP2008536807A (ja)	2008-09-11
CN101155823A (zh)	2008-04-02
IL185608A (en)	2016-06-30
IL185608A0 (en)	2008-01-06
EA019560B1 (ru)	2014-04-30
US7875599B2 (en)	2011-01-25
ATE482969T1 (de)	2010-10-15
EP2206719A3 (en)	2011-01-05
EP2206719A2 (en)	2010-07-14
HK1115387A1 (en)	2008-11-28
EP1853619B1 (en)	2010-09-29
ES2353413T3 (es)	2011-03-01

Legal Events

Date	Code	Title	Description
2013-10-16	C06	Publication
2013-10-16	PB01	Publication
2013-11-13	C10	Entry into substantive examination
2013-11-13	SE01	Entry into force of request for substantive examination
2017-03-29	RJ01	Rejection of invention patent application after publication
2017-03-29	RJ01	Rejection of invention patent application after publication	Application publication date: 20131016

Publication	Publication Date	Title
CN103349664A (zh)	2013-10-16	含甾族的c-17苯并吡咯的组合物
US10098896B2 (en)	2018-10-16	C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity
Handratta et al.	2005	Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model
US6200965B1 (en)	2001-03-13	17-Azolyl steroids useful as androgren synthesis inhibitors
KR20150036319A (ko)	2015-04-07	3-치환된 에스트라-1,3,5(10),16-테트라엔 유도체, 그의 제조방법, 이를 포함하는 약학 제제 및 의약품 제조를 위한 그의 용도
CA2978454A1 (en)	2016-09-15	Altering steroid metabolism for treatment of steroid-dependent disease
AU2005259329B2 (en)	2011-11-10	Novel 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17Beta-hydroxysteroid dehydrogenase type 1
US7732493B2 (en)	2010-06-08	2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
SK40895A3 (en)	1995-07-11	17-beta-substituted 4-azaandrostane derivatives, pharmaceutical compositions containing them and process for preparing same
HK1115387B (en)	2011-09-16	3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androsta-5,16-diene for use in the treatment of a prostate disease
CZ300376B6 (cs)	2009-05-06	Ligandy estrogenových receptoru alfa a beta, zpusob jejich prípravy a farmaceutické prostredky, které je obsahují
Salvador et al.	2013	Treatment: From Concept to Clinic

CN103349664A - 含甾族的c-17苯并吡咯的组合物 - Google Patents

Info

Links

Images

Classifications

Landscapes

Applications Claiming Priority (2)

Related Parent Applications (1)

Publications (1)

Family

ID=36941503

Family Applications (2)

Family Applications After (1)

Country Status (21)

Cited By (1)

Families Citing this family (35)

Family Cites Families (6)

Non-Patent Citations (1)

Cited By (1)

Also Published As

Similar Documents

Legal Events